' Frame Running' May Help Boost Physical Activity in MS'Frame Running' May Help Boost Physical Activity in MS
People with multiple sclerosis and moderate-to-severe walking disability could engage in physical activity and improve their physical function with an adapted running frame, suggests new research.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - October 23, 2023 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news
S1P Receptor Modulator May Boost Cognitive Processing Speed in Early MS
(MedPage Today) -- Treatment with ozanimod (Zeposia) led to clinically meaningful improvement in cognitive processing speed among people with early relapsing multiple sclerosis (RMS), an ad hoc interim analysis of the phase IIIb ENLIGHTEN trial... (Source: MedPage Today Neurology)
Source: MedPage Today Neurology - October 19, 2023 Category: Neurology Source Type: news
‘The Sopranos’’ Jamie-Lynn Sigler Opens Up About Multiple Sclerosis
At 20, Jamie-Lynn Sigler was starring in the biggest show on TV. 'The Sopranos'' star was on top of the world —until she wasn't. Sigler shares her multiple sclerosis story (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - October 19, 2023 Category: Pharmaceuticals Authors: Lipi Roy, MD, MPH, Contributor Tags: Healthcare /healthcare Innovation /innovation Business /business Hollywood & Entertainment /hollywood-entertainment pharma standard Source Type: news
‘Sopranos’ Star Jamie-Lynn Sigler Opens Up About Multiple Sclerosis
At 20, Jamie-Lynn Sigler was starring in the biggest show on TV. 'The Sopranos'' star was on top of the world —until she wasn't. Sigler shares her multiple sclerosis story (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - October 19, 2023 Category: Pharmaceuticals Authors: Lipi Roy, MD, MPH, Contributor Tags: Healthcare /healthcare Innovation /innovation Business /business Hollywood & Entertainment /hollywood-entertainment pharma standard Source Type: news
BTK Inhibitor Reduces Brain Lesions in Relapsing MS
(MedPage Today) -- MILAN -- Investigational fenebrutinib reduced brain lesions in relapsing multiple sclerosis (MS) patients and showed evidence of central nervous system (CNS) penetration, data from the phase II FENopta study showed.
Compared... (Source: MedPage Today Neurology)
Source: MedPage Today Neurology - October 19, 2023 Category: Neurology Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports good sales growth despite decline in demand for COVID-19 products
Basel, 19 October 2023Groupsales grow by 1%1at constant exchange rates (CER) in the first nine months, showing a strong increase of 7% in the third quarterExcluding COVID-19 products,Group salesincrease by 9%Pharmaceuticals Division sales grow by 9%, driven by continued high demand for newer medicinesDiagnostics Division ’s base businessincreases by 7%;overall divisional sales are down 18% due to a surge in demand for COVID-19 tests in 2022Highlightsin the third quarter of 2023:EU approval ofEvrysdifor babies under two months old with spinal muscular atrophyFirst approval of subcutaneous form of cancer immunotherapyTecen...
Source: Roche Media News - October 19, 2023 Category: Pharmaceuticals Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports good sales growth despite decline in demand for COVID-19 products
Groupsales grow by 1%1at constant exchange rates (CER) in the first nine months, showing a strong increase of 7% in the third quarterExcluding COVID-19 products,Group salesincrease by 9%Pharmaceuticals Division sales grow by 9%, driven by continued high demand for newer medicinesDiagnostics Division ’s base businessincreases by 7%;overall divisional sales are down 18% due to a surge in demand for COVID-19 tests in 2022Highlightsin the third quarter of 2023:EU approval ofEvrysdifor babies under two months old with spinal muscular atrophyFirst approval of subcutaneous form of cancer immunotherapyTecentriqPositive phase III...
Source: Roche Investor Update - October 19, 2023 Category: Pharmaceuticals Source Type: news
Neurofilament Light Predicts MS Worsening in Silent Progression
(MedPage Today) -- Neuroaxonal pathology occurred in advance of -- not coincident with -- clinical worsening in multiple sclerosis (MS), particularly in patients with "silent progression" or progression independent of relapse activity (PIRA... (Source: MedPage Today Neurology)
Source: MedPage Today Neurology - October 17, 2023 Category: Neurology Source Type: news
MS-Specific Internet-Based Therapy Program Can Cut Depressive Symptoms
TUESDAY, Oct. 17, 2023 -- A multiple sclerosis (MS)-specific internet-based cognitive behavioral therapy (iCBT) program can reduce depressive symptoms among patients with MS, according to a study published in the October issue of The Lancet Digital... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - October 17, 2023 Category: Pharmaceuticals Source Type: news
MS-Tailored Weight Loss Program Achieves Meaningful Results MS-Tailored Weight Loss Program Achieves Meaningful Results
People with multiple sclerosis and obesity can achieve substantial weight loss, leading to improved mobility and quality of life, with a specially designed program, new trial results suggest.Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - October 16, 2023 Category: Endocrinology Tags: Neurology & Neurosurgery News Source Type: news
Path to Multiple Sclerosis Cure on the Horizon
(MedPage Today) -- MILAN -- A path to a cure for multiple sclerosis (MS) may be on the horizon, a top MS researcher suggested.
The field faces a great opportunity to advance from suppressing the disease to curing it, said Stephen Hauser, MD... (Source: MedPage Today Neurology)
Source: MedPage Today Neurology - October 16, 2023 Category: Neurology Source Type: news
Subcutaneous Ocrelizumab Not Inferior to IV Infusion
(MedPage Today) -- MILAN -- An investigational 10-minute subcutaneous injection of ocrelizumab (Ocrevus) was non-inferior to the established IV infusion formulation of the drug in multiple sclerosis (MS), the phase III OCARINA II trial showed... (Source: MedPage Today Neurology)
Source: MedPage Today Neurology - October 14, 2023 Category: Neurology Source Type: news
Late-breaking data for Roche ’s BTK inhibitor fenebrutinib show brain penetration and significant reduction in lesions in patients with relapsing multiple sclerosis
New data from Phase II FENopta study in relapsing multiple sclerosis (RMS) show fenebrutinib crosses the blood-brain barrier with the potential to act directly on the chronic inflammation related to multiple sclerosis (MS)More than 90% relative reduction in new/enlarging T2 lesions and new T1 gadolinium-enhancing (Gd+) lesions with fenebrutinib beginning at 8 weeksThe safety profile of fenebrutinib was consistent with previous and ongoing clinical trials across more than 2,500 people to dateBasel, 13 October 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced new data from the Phase II FENopta study showing that inve...
Source: Roche Media News - October 13, 2023 Category: Pharmaceuticals Source Type: news
Late-breaking data for Roche ’s BTK inhibitor fenebrutinib show brain penetration and significant reduction in lesions in patients with relapsing multiple sclerosis
New data from Phase II FENopta study in relapsing multiple sclerosis (RMS) show fenebrutinib crosses the blood-brain barrier with the potential to act directly on the chronic inflammation related to multiple sclerosis (MS)More than 90% relative reduction in new/enlarging T2 lesions and new T1 gadolinium-enhancing (Gd+) lesions with fenebrutinib beginning at 8 weeksThe safety profile of fenebrutinib was consistent with previous and ongoing clinical trials across more than 2,500 people to dateBasel, 13 October 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced new data from the Phase II FENopta study showing that inve...
Source: Roche Investor Update - October 13, 2023 Category: Pharmaceuticals Source Type: news
Novel Drug Shows Promise in Multiple Sclerosis
(MedPage Today) -- MILAN -- Treatment with investigational frexalimab, a novel CD40 ligand (CD40L) inhibitor, led to sustained reduction of MRI disease activity in relapsing multiple sclerosis (MS) at 6 months, follow-up data from a phase II... (Source: MedPage Today Neurology)
Source: MedPage Today Neurology - October 13, 2023 Category: Neurology Source Type: news
